Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kareus, Quintiles In Strategic Development Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Kareus, Quintiles In Strategic Development Pact

Kareus Therapeutics SA has entered a broad strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials.

Kareus Therapeutics SA has entered a broad strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials. Quintiles will make an undisclosed investment in Kareus through an equity investment and access to clinical service on a shared-risk basis. Kareus plans to submit an IND application for KU-046, a new chemical entity for the treatment of Alzheimer’s disease. Kareus has also identified a lead series of molecules for the treatment of Type-2 diabetes and will select a clinical candidate for development later in 2011. Quintiles will conduct Phase I trials for both KU-046 and the diabetes candidate.

Tom Perkins, senior vice president of corporate development for Quintiles, said, “This agreement is an example of how leading biotechnology companies are building partnerships that extend beyond the traditional licensing model to manage risk, increase productivity, and increase value to stakeholders. We are pleased that Kareus has chosen to leverage Quintiles’ suite of comprehensive services, including our new Phase I research unit in Hyderabad, India.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters